There are 292 studies (219 are peer-reviewed) proving the effectiveness of hydroxychloroquine as both a treatment and prophylaxis against COVID-19.
Coronavirus cases are plummeting in India thanks to new rules that promote Ivermectin and hydroxychloroquine to its massive population.
Of course, the WHO and pharmaceutical companies are having fits.
This is despite the fact that lives are being saved.
The COVID Blog reported:
India has received the baton for title of COVID Capitol of the World after China, Italy and the United States held it for much of last year.
The world second-most populace country after China had fewer than 138,000 total active COVID cases in early February 2021. That’s the lowest figure since January 2020. India active COVID cases sit around 3.6 million today, according to the India Ministry of Health and Family Welfare. Mainstream media are blaming the massive spike on a “scary, mutant variant” called B.1.617…
…The India health ministry updated its guidelines on April 28 for quarantines, treating the asymptomatic and those with mild symptoms of COVID-19. The agency now says that asymptomatic patients should “consider Tab Ivermectin (200 mcg/kg once a day, to be taken empty stomach) for 3 to 5 days.” Caregivers of patients in quarantine are instructed to “take Hydroxychloroquine prophylaxis as per protocol and as prescribed by the treating medical officer.” See the full document here.
There are 292 studies (219 are peer-reviewed) proving the effectiveness of hydroxychloroquine as both a treatment and prophylaxis against COVID-19. Ivermectin has 93 studies (54 peer-reviewed) showing its effectiveness as treatment and prophylaxis against COVID-19. Despite the now-indisputable fact that these drugs essentially kill COVID-19 within hours or days, the Bill Gates-funded World Health Organization (WHO) and big pharma are having fits over India’s new guidelines and the results.
And now the COVID cases are plummeting.
And the active cases in India are also plummeting.
Of course, this will not make any headlines.